There are currently 48 active clinical trials seeking participants for Amyotrophic Lateral Sclerosis research studies. The states with the highest number of trials for Autism participants are California, Florida, Pennsylvania and New York.
RAPA-501 Therapy for ALS
NCT04220190
Recruiting
RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).
Gender:
All
Ages:
18 years and above
Trial Updated:
08/25/2023
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)
NCT05039099
Recruiting
The purpose of this study is to evaluate the safety, tolerability, PK, and PD of AP-101 in participants with fALS and sALS.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/02/2023
Locations: UC San Diego, ACTRI, La Jolla, California +12 locations
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
Studies in Amyotrophic Lateral Sclerosis (ALS) and Other Neurodegenerative Motor Neuron Disorders
NCT05474235
Recruiting
The purpose of this study is to collect, from patients with sporadic and familial ALS and their family members, clinical data and blood samples for extraction of DNA, RNA, preparation of lymphocytes, plasma and serum to establish a repository for future investigations of genetic contributions to ALS pathogenesis. Blood samples for DNA extraction also would be collected from control subjects with no personal or family history of ALS phenotypes.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/01/2023
Locations: Mayo Clinic Florida, Jacksonville, Florida
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
Telehealth Implementation of Brain-Computer Interface
NCT05951556
Recruiting
Determine if Telehealth intervention can allow/empower a caregiver (who is untrained) to effectively implement and utilize a Brain-Computer Interface for communication with a participant who is "Locked in" following progression of Amyotrophic Lateral Sclerosis and other conditions.
Gender:
All
Ages:
Between 16 years and 100 years
Trial Updated:
07/18/2023
Locations: ShirleyRyan AbilityLab, Chicago, Illinois
Conditions: Amyotrophic Lateral Sclerosis, Stroke
Register for Updates
Intermuscular Coherence as a Biomarker for ALS
NCT05104710
Recruiting
The specific aims of this study are to: Determine if a painless and quick measurement of muscle activity using surface electrodes can help with the diagnosis of ALS. Specifically, we ask if a measure of intermuscular coherence (IMC-βγ), when added to current diagnostic criteria (Awaji criteria), can differentiate ALS from mimic diseases more accurately and earlier than currently possible. Characterize IMC-βγ in neurotypical subjects by age, sex, race, and ethnicity. Follow a cohort of ALS patie... Read More
Gender:
All
Ages:
Between 20 years and 80 years
Trial Updated:
05/16/2023
Locations: University of California Center for Clinical Research, Irvine, California +2 locations
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
NCT03127267
Recruiting
The objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Gender:
All
Ages:
Between 18 years and 81 years
Trial Updated:
04/14/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama +55 locations
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
NuroSleeve Powered Brace & Stimulation System to Restore Arm Function
NCT04798378
Recruiting
The purpose of this study is to investigate if a person with weakness or paralysis in one or both arms, can use the NuroSleeve combined powered arm brace (orthosis) and muscle stimulation system to help restore movement in one arm sufficient to perform daily activities. This study could lead to the development of a product that could allow people with arm weakness or arm paralysis to use the NuroSleeve and similar devices to improve arm health and independent function.
Gender:
All
Ages:
4 years and above
Trial Updated:
04/11/2023
Locations: Nemours Children's Hospital, Wilmington, Delaware +1 locations
Conditions: Neurologic Diseases, Hemiparesis, Quadriplegia, Muscular Dystrophies, Arthrogryposis, Spinal Cord Injuries, Charcot-Marie-Tooth, Stroke, Weakness of Extremities as Sequela of Stroke, Weakness Due to Upper Motor Neuron Dysfunction, Amyotrophic Lateral Sclerosis, Spinal Muscular Atrophy, Arm Paralysis, Cerebral Palsy
Register for Updates
Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)
NCT04569435
Recruiting
This study is a multi-center, open-label study of intravenous (IV) ANX005 in participants with ALS.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/23/2023
Locations: Annexon Investigational Site 04, Phoenix, Arizona +10 locations
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
AMDX-2011P Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy
NCT05542576
Recruiting
The purpose of this research study is to assess safety and tolerability of a single intravenous (given through a vein) dose of the investigational retinal tracer AMDX-2011P in patients with neurodegenerative diseases (Parkinson's disease and ALS).
Gender:
All
Ages:
18 years and above
Trial Updated:
01/31/2023
Locations: Eye Research Foundation, Newport Beach, California +1 locations
Conditions: Parkinson Disease, Amyotrophic Lateral Sclerosis
Register for Updates
Analysis of Human ALS Tissues and Registry of ALS Patients
NCT05067179
Recruiting
Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig's Disease, is a progressive, terminal condition of muscle weakness that is associated with degeneration of neurons in the spinal cord and brain. This devastating disorder afflicts people in the prime of their lives. At the present time, there are no cures for this disorder, and current treatments are marginal at best. Despite years of intensive research, a fundamental understanding of this disease is still lacking. There is a n... Read More
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
11/03/2022
Locations: University of Illinois at Chicago, Chicago, Illinois
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
Outcomes Mandate National Integration With Cannabis as Medicine
NCT03944447
Recruiting
This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.
Gender:
All
Ages:
7 years and above
Trial Updated:
05/29/2022
Locations: OMNI Medical Services, Boca Raton, Florida +16 locations
Conditions: Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
Register for Updates
A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers
NCT05279755
Recruiting
This trial is a Phase 1a/1b, randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of prosetin administered to healthy adult subjects.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/06/2022
Locations: Worldwide Clinical Trials Early Phase Services, San Antonio, Texas
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates